Nektar Therapeutics (NKTR) said Thursday that its experimental cancer treatment, NKTR-255, combined with durvalumab, sped up the recovery of immune cells in patients who had completed radiation therapy.
The interim analysis of the phase 2 study showed that NKTR-255 reversed radiation-induced lymphopenia in patients with locally advanced non-small cell lung cancer, according to the company.
Nektar said NKTR-255, when combined with durvalumab after radiation therapy, significantly improved the recovery of lymphocytes after 8 weeks compared to patients who received radiation therapy alone or radiation therapy with durvalumab.
Shares of the company were down 2.1% in recent trading.
Price: 1.37, Change: -0.02, Percent Change: -1.44
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.